Boehringer, Sosei ink GPCR agonist pact to tackle all symptoms of schizophrenia

2024-03-11

引进/卖出临床1期

Boehringer Ingelheim partnered with Sosei Heptares Sosei Heptares to develop a schizophrenia treatment targeting the G protein-coupled receptor GPR52 in the hopes of addressing all three symptom clusters associated with the condition.

Under the agreement, Boehringer Ingelheim has an option to exclusively license Sosei’s portfolio of GPR52 agonists GPR52 agonists following the completion of an ongoing Phase Ia trial and a subsequent Phase Ib study of the lead candidate, dubbed HTL0048149. Initial data from the early-stage study of HTL0048149 – a once-daily, oral drug - are expected in 2025.

The portfolio also contains a number of differentiated back-up compounds designed by Sosei using its StaR technology and structure-based drug design (SBDD) platform.

Boehringer Ingelheim will make an upfront payment of €25 million ($27 million), with Sosei set to receive a further €60-million ($66 million) option exercise payment, as well as further milestones totalling up to €670 million ($733 million) and tiered sales royalties.

Matt Barnes, head of UK R&D at Sosei, remarked “this collaboration highlights the significant potential GPR52 has shown in preclinical research.” The companies noted that the receptor is located in the two areas of the brain that drive the positive and the negative and cognitive symptoms of schizophrenia.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构